Antithrombotic therapy for percutaneous coronary intervention.
This article outlines the antiplatelet and antithrombotic therapy used in contemporary percutaneous coronary interventions. It is a comprehensive review of past and present pharmacologic agents and includes a discussion of the more promising potential future therapies. The clinical trials that provide the basis for the current standard of care are provided, as are ongoing trials that will likely shape the future standard. This article is not intended to provide a detailed discussion of precise mechanistic or structural features of each agent but to serve as a practical clinical guide to the interventionalist when choosing specific pharmacotherapies for specific patients in the catheterization laboratory.
Barman
Nitin
N
Interventional Cardiology, Mount Sinai Hospital, One Gustave L. Levy Place, New York, NY 10029, USA.
Bhatt
Deepak L
DL
D015906:Angioplasty, Balloon, Coronary; D003131:Combined Modality Therapy; D003327:Coronary Disease / Q000401:mortality / Q000628:therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000494:pharmacology; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000494:pharmacology; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors
D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex